New Haven Pharmaceuticals announced the launch of Durlaza (aspirin extended-release) capsules for the secondary prevention of stroke and acute cardiac events, including myocardial infarction in high-risk cardiovascular patients. It was approved by the Food and Drug Administration (FDA) in September 2015.
Durlaza uses extended-release, microcapsule technology to prolong aspirin release. The 24-hour delivery helps maximize its benefit by providing sustained platelet inhibition with the potential for improved patient adherence and compliance.
Durlaza works by inhibiting prostaglandin synthesis which results in inhibition of platelet aggregation for their lifespan of about 7 to 10 days. The acetyl group of aspirin binds with a serine residue of COX-1 resulting in irreversible inactivation of the enzyme. Inhibition of COX-1 prevents conversion of arachidonic acid to thromboxane A2, a potent agonist of platelet aggregation.
Durlaza is available as 162.5mg strength capsules in 30- and 90-count bottles.
For more information call (877) 824-2483 or visit Durlaza.com.